Clinical Trial Update: Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating immunogenicity, safety, and reactogenicity of Rotavac in healthy infants aged 6-8 weeks in Vietnam.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infection

Drugs mentioned

• Rotavac

Snippet

Sponsor: Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products | Conditions: Rotavirus Infections | Phase 3 | Status: UNKNOWN